REFERENCES
3. Motzer RJ, Jonasch E, Boyle S, et al. NCCN guidelines insights: kidney cancer, version 1.2021. J Natl Compr Canc Netw 2020;18:1160-70.
4. Zaid HB, Parker WP, Safdar NS, et al. Outcomes following complete surgical metastasectomy for patients with metastatic renal cell carcinoma: a systematic review and meta-analysis. J Urol 2017;197:44-9.
5. Soares A, Monteiro FSM, Maluf FC, et al. Advanced renal cell carcinoma (RCC) management: an expert panel recommendation from the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG). J Cancer Res Clin Oncol 2020;146:1829-45.
6. Kavolius JP, Mastorakos DP, Pavlovich C, Russo P, Burt ME, Brady MS. Resection of metastatic renal cell carcinoma. J Clin Oncol 1998;16:2261-6.
7. der Poel HG, Roukema JA, Horenblas S, van Geel AN, Debruyne FM. Metastasectomy in renal cell carcinoma: a multicenter retrospective analysis. Eur Urol 1999;35:197-203.
8. Alt AL, Boorjian SA, Lohse CM, Costello BA, Leibovich BC, Blute ML. Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer 2011;117:2873-82.
9. Ng CS, Wood CG, Silverman PM, Tannir NM, Tamboli P, Sandler CM. Renal cell carcinoma: diagnosis, staging, and surveillance. AJR Am J Roentgenol 2008;191:1220-32.
10. Vikram R, Beland MD, Blaufox MD, et al. ACR appropriateness criteria renal cell carcinoma staging. J Am Coll Radiol 2016;13:518-25.
11. Win AZ, Aparici CM. Clinical effectiveness of (18)f-fluorodeoxyglucose positron emission tomography/computed tomography in management of renal cell carcinoma: a single institution experience. World J Nucl Med 2015;14:36-40.
12. Verhoeff SR, van Es SC, Boon E, et al. Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma. Eur J Nucl Med Mol Imaging 2019;46:1931-9.
13. Pfannschmidt J, Hoffmann H, Muley T, Krysa S, Trainer C, Dienemann H. Prognostic factors for survival after pulmonary resection of metastatic renal cell carcinoma. Ann Thorac Surg 2002;74:1653-7.
14. Bölükbas S, Kudelin N, Eberlein M, Fisseler-Eckhoff A, Schirren J. The influence of the primary tumor on the long-term results of pulmonary metastasectomy for metastatic renal cell carcinoma. Thorac Cardiovasc Surg 2012;60:390-7.
15. Kudelin N, Bölükbas S, Eberlein M, Schirren J. Metastasectomy with standardized lymph node dissection for metastatic renal cell carcinoma: an 11-year single-center experience. Ann Thorac Surg 2013;96:265-70: discussion 270-1.
16. Saricam M. Factors affecting long-term survival following pulmonary metastasectomy of renal cell carcinoma. Urol J 2020;17:492-6.
17. Kume H, Kakutani S, Yamada Y, et al. Prognostic factors for renal cell carcinoma with bone metastasis: who are the long-term survivors? J Urol 2011;185:1611-4.
18. Huang Z, Du Y, Zhang X, Liu H, Liu S, Xu T. Clear cell renal cell carcinoma bone metastasis: what should be considered in prognostic evaluation. Eur J Surg Oncol 2019;45:1246-52.
19. Kollender Y, Bickels J, Price WM, et al. Metastatic renal cell carcinoma of bone: indications and technique of surgical intervention. J Urol 2000;164:1505-8.
20. Higuchi T, Yamamoto N, Hayashi K, et al. Long-term patient survival after the surgical treatment of bone and soft-tissue metastases from renal cell carcinoma. Bone Joint J 2018;100-B:1241-8.
21. Lin PP, Mirza AN, Lewis VO, et al. Patient survival after surgery for osseous metastases from renal cell carcinoma. J Bone Joint Surg Am 2007;89:1794-801.
22. Ptashnikov D, Zaborovskii N, Kostrickii S, et al. Metastasectomy and targeted therapy for patients with spinal metastases of renal cell carcinoma. Int J Spine Surg 2020;14:982-8.
23. Amini A, Altoos B, Bourlon MT, et al. Local control rates of metastatic renal cell carcinoma (RCC) to the bone using stereotactic body radiation therapy: Is RCC truly radioresistant? Pract Radiat Oncol 2015;5:e589-96.
24. Jhaveri PM, Teh BS, Paulino AC, et al. A dose-response relationship for time to bone pain resolution after stereotactic body radiotherapy (SBRT) for renal cell carcinoma (RCC) bony metastases. Acta Oncol 2012;51:584-8.
25. Martel G, Bertens KA, Canil C. Surgical management of genitourinary cancer liver metastases. Surg Oncol Clin N Am 2021;30:89-102.
26. Ruys AT, Tanis PJ, Nagtegaal ID, et al. Surgical treatment of renal cell cancer liver metastases: a population-based study. Ann Surg Oncol 2011;18:1932-8.
27. Staehler MD, Kruse J, Haseke N, et al. Liver resection for metastatic disease prolongs survival in renal cell carcinoma: 12-year results from a retrospective comparative analysis. World J Urol 2010;28:543-7.
28. Joyce DD, Psutka SP, Groeschl RT, et al. Complications and outcomes associated with surgical management of renal cell carcinoma involving the liver: a matched cohort study. Urology 2017;99:155-61.
29. Wroński M, Arbit E, Russo P, Galicich JH. Surgical resection of brain metastases from renal cell carcinoma in 50 patients. Urology 1996;47:187-93.
30. Capitanio U, Becker F, Blute ML, et al. Lymph node dissection in renal cell carcinoma. Eur Urol 2011;60:1212-20.
31. Blom JH, van Poppel H, Maréchal JM, et al. EORTC Genitourinary Tract Cancer Group. Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881. Eur Urol 2009;55:28-34.
32. Pantuck AJ, Zisman A, Dorey F, et al. Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection. J Urol 2003;169:2076-83.
33. Feuerstein MA, Kent M, Bernstein M, Russo P. Lymph node dissection during cytoreductive nephrectomy: a retrospective analysis. Int J Urol 2014;21:874-9.
34. Gershman B, Thompson RH, Moreira DM, et al. Radical nephrectomy with or without lymph node dissection for nonmetastatic renal cell carcinoma: a propensity score-based analysis. Eur Urol 2017;71:560-7.
35. John NT, Blum KA, Hakimi AA. Role of lymph node dissection in renal cell cancer. Urol Oncol 2019;37:187-92.
36. Ouzaid I, Capitanio U, Staehler M, et al. Young Academic Urologists Kidney Cancer Working Group of the European Association of Urology. Surgical metastasectomy in renal cell carcinoma: a systematic review. Eur Urol Oncol 2019;2:141-9.
37. Ishihara H, Takagi T, Kondo T, et al. Prognostic impact of metastasectomy in renal cell carcinoma in the postcytokine therapy era. Urol Oncol 2021;39:77.e17-25.
38. Takagi T, Fukuda H, Ishihara H, et al. Predictive factors for recurrence after complete metastasectomy in patients with metastatic renal cell carcinoma in the targeted therapy era. Urol Oncol 2020;38:515-20.
39. Palumbo C, Pecoraro A, Knipper S, et al. Survival and complication rates of metastasectomy in patients with metastatic renal cell carcinoma treated exclusively with targeted therapy: a combined population-based analysis. Anticancer Res 2019;39:4357-61.
40. Meyer CP, Sun M, Karam JA, et al. Complications after metastasectomy for renal cell carcinoma-a population-based assessment. Eur Urol 2017;72:171-4.
41. Karam JA, Rini BI, Varella L, et al. Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma. J Urol 2011;185:439-44.
42. Li JR, Ou YC, Yang CK, et al. The impact of local intervention combined with targeted therapy on metastatic renal cell carcinoma. Anticancer Res 2018;38:5339-45.
43. Procopio G, Apollonio G, Cognetti F, et al. Sorafenib versus observation following radical metastasectomy for clear-cell renal cell carcinoma: results from the phase 2 randomized open-label RESORT study. Eur Urol Oncol 2019;2:699-707.
44. Appleman LJ, Puligandla M, Pal SK, et al. Randomized, double-blind phase III study of pazopanib versus placebo in patients with metastatic renal cell carcinoma who have no evidence of disease following metastasectomy: a trial of the ECOG-ACRIN cancer research group (E2810). J Clin Oncol 2019;37:4502.
45. Rausch S, Gouttefangeas C, Hennenlotter J, et al. Results of a phase 1/2 study in metastatic renal cell carcinoma patients treated with a patient-specific adjuvant multi-peptide vaccine after resection of metastases. Eur Urol Focus 2019;5:604-7.
46. Ishihara H, Takagi T, Kondo T, Fukuda H, Yoshida K, Tanabe K. Nivolumab treatment beyond progression for metastatic renal cell carcinoma: New role of metastasectomy in the immune checkpoint inhibitor era? Int J Urol 2020;27:691-2.
47. Dragomir A, Nazha S, Wood LA, et al. Outcomes of complete metastasectomy in metastatic renal cell carcinoma patients: The Canadian Kidney Cancer information system experience. Urol Oncol 2020;38:799.e1-799.e10.
48. Lyon TD, Thompson RH, Shah PH, et al. Complete surgical metastasectomy of renal cell carcinoma in the post-cytokine era. J Urol 2020;203:275-82.
49. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001;345:1655-9.
50. Mickisch G, Garin A, van Poppel H, de Prijck L, Sylvester R. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001;358:966-70.
51. Méjean A, Ravaud A, Thezenas S, et al. Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N Engl J Med 2018;379:417-27.
52. Massari F, Di Nunno V, Gatto L, et al. Should CARMENA really change our attitude towards cytoreductive nephrectomy in metastatic renal cell carcinoma? Target Oncol 2018;13:705-14.
53. Bex A, Mulders P, Jewett M, et al. Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME randomized clinical trial. JAMA Oncol 2019;5:164-70.
54. Bhindi B, Abel EJ, Albiges L, et al. Systematic review of the role of cytoreductive nephrectomy in the targeted therapy era and beyond: an individualized approach to metastatic renal cell carcinoma. Eur Urol 2019;75:111-28.
55. Gao J, Karam JA, Tannir NM, et al. A pilot randomized study evaluating nivolumab (nivo) or nivo + bevacizumab (bev) or nivo + ipilimumab (ipi) in patients with metastatic renal cell carcinoma (MRCC) eligible for cytoreductive nephrectomy (CN), metastasectomy (MS) or posttreatment biopsy (Bx). J Clin Oncol 2018;36:4520.
56. Singla N, Hutchinson RC, Ghandour RA, et al. Improved survival after cytoreductive nephrectomy for metastatic renal cell carcinoma in the contemporary immunotherapy era: An analysis of the National Cancer Database. Urol Oncol 2020;38:604.e9-604.e17.
57. Liu J, Blake SJ, Yong MC, et al. Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease. Cancer Discov 2016;6:1382-99.
58. Clark DJ, Dhanasekaran SM, Petralia F, et al. Clinical Proteomic Tumor Analysis Consortium. Integrated proteogenomic characterization of clear cell renal cell carcinoma. Cell 2020;180:207.
60. Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science 2018;359:801-6.
61. Verbiest A, Couchy G, Job S, et al. Molecular subtypes of clear-cell renal cell carcinoma are prognostic for outcome after complete metastasectomy. Eur Urol 2018;74:474-80.
